A possible advantage of combining tumor suppressor gene therapy with small molecule targeted therapy, such as erlotinib, is enhancement of sensitivity that may extend over wild type EGFR cell types with differing mechanisms of drug resistance. The gene discussed is EGFR; the disease is neoplasm.